Department of Obstetrics and Gynecology, Kaiser Permanente Oakland Medical Center, Oakland, CA.
Department of Obstetrics and Gynecology, Kaiser Permanente Oakland Medical Center, Oakland, CA.
Am J Obstet Gynecol. 2021 Nov;225(5):540.e1-540.e8. doi: 10.1016/j.ajog.2021.04.257. Epub 2021 May 4.
Fetomaternal hemorrhage is associated with severe fetal morbidity and mortality. The recurrence risk of fetomaternal hemorrhage is unknown.
We sought to establish the recurrence rate of fetomaternal hemorrhage in a large integrated healthcare system over a 10-year period.
In this retrospective study within the Kaiser Permanente Northern California medical system, cases of fetomaternal hemorrhage were defined by either an elevated fetal hemoglobin level as determined by flow cytometry for a concerning pregnancy outcome (preterm delivery, perinatal demise, neonatal anemia, or transfusion within the first 2 days of life) or by perinatal demise with autopsy findings suggestive of fetomaternal hemorrhage. The outcomes of subsequent pregnancies were reviewed for features of recurrence.
Within the 2008 to 2018 birth cohort of 375,864 pregnancies, flow cytometry testing for fetal hemoglobin levels was performed in 20,582 pregnancies. We identified 340 cases of fetomaternal hemorrhage (approximately 1 in 1100 births). Within the cohort of 340 affected pregnancies, perinatal loss was recorded for 80 (23.5%) pregnancies and 50 (14.7%) pregnancies delivered neonates who required transfusion. The affected patients had 225 subsequent pregnancies of which 210 were included in the analysis. Of these, 174 (82.9%) advanced beyond the threshold of viability and were delivered within our healthcare system. There was 1 case of recurrent fetomaternal hemorrhage identified. The recurrent case involved a spontaneous preterm delivery of an infant who was noted to have an elevated reticulocyte count but was clinically well.
Within our large integrated healthcare system, approximately 1 in 1100 pregnancies was affected by fetomaternal hemorrhage within a 10-year period, which is comparable with previous studies. We identified 1 case of recurrence, yielding a recurrence rate of 0.5%. This infant did not have features of clinically important fetomaternal hemorrhage. This information can inform counseling of patients with affected pregnancies.
母婴血液转移与严重的胎儿发病率和死亡率有关。母婴血液转移的复发风险尚不清楚。
我们旨在在一个大型综合医疗保健系统中,在 10 年内确定母婴血液转移的复发率。
在 Kaiser Permanente Northern California 医疗系统内,这项回顾性研究通过流式细胞术确定胎儿血红蛋白水平升高来定义母婴血液转移病例,该水平升高是由于妊娠结局不良(早产、围产儿死亡、新生儿贫血或出生后 2 天内输血)或围产儿死亡且尸检结果提示有母婴血液转移。回顾了随后妊娠的特征,以评估其复发情况。
在 2008 年至 2018 年的分娩队列中,有 375864 例妊娠接受了胎儿血红蛋白水平的流式细胞术检测。我们确定了 340 例母婴血液转移(约每 1100 例分娩中有 1 例)。在 340 例受影响的妊娠中,有 80 例(23.5%)妊娠发生围产儿死亡,50 例(14.7%)分娩的新生儿需要输血。受影响的患者有 225 次后续妊娠,其中 210 次纳入分析。其中,174 次(82.9%)妊娠进展超过生存阈值并在我们的医疗保健系统内分娩。发现 1 例母婴血液转移复发。复发病例涉及一例自发性早产婴儿,该婴儿的网织红细胞计数升高,但临床状况良好。
在我们的大型综合医疗保健系统中,大约每 1100 次妊娠中就有 1 次在 10 年内受到母婴血液转移的影响,这与之前的研究相似。我们确定了 1 例复发病例,复发率为 0.5%。该婴儿没有出现临床上明显的母婴血液转移的特征。这些信息可以为受影响妊娠的患者提供咨询。